Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/14—Antitussive agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

• the present invention relates to the use of non-steroidal anti-inflammatory drugs as antitussive and to their use for the manufacture of a medicament for the treatment of nonproductive cough associated with disorders of the respiratory organs caused by viruses or bacteria, especially common colds.
• the invention also relates to pharmaceutical formulations for the treatment of nonproductive cough associated with viral or bacterial disease of the respiratory organs which comprise a combination of at least one non-steroidal anti-inflammatory drug with at least one antitussive.
• Ibuprofen is an arylpropionic acid derivative whose pain-relieving (analgesic), fever-reducing (antipyretic) and inflammation-inhibiting (anti-inflammatory) effect has been known for a long time. It is used as active ingredient in a large number of medicaments for oral, parenteral and topical or rectal administration. Ibuprofen-containing products are employed as means for treating mild to moderately severe pain such as headache, toothache, sore throat, period pain, joint pain, backache, and in the treatment of the acute headache phase in migraine with and without aura and the treatment of tension headaches.
• Ibuprofen-containing products are also employed for the symptomatic treatment of febrile conditions.
• Ibuprofen is an active ingredient belonging to the group of non-steroidal anti-inflammatory drugs.
• Non-steroidal anti-inflammatory drugs are inhibitors of cyclooxygenases and can be obtained commercially in a number of different oral and parenteral dosage forms. Creams and gels are available for topical application of nonselective cyclooxygenase inhibitors. Also available as further parenteral dosage forms are suppositories and solutions for injection. Parenteral dosage forms for selective inhibitors of cyclooxygenase 2 are unavailable, at least commercially.
• Dosage forms available for oral administration of non-steroidal anti-inflammatory drugs are tablets, film-coated tablets, slow-release tablets, sugar-coated tablets, capsules, slow-release capsules, granules, suspensions and effervescent tablets.
• ibuprofen-containing products are used for treating the symptoms of common colds caused by viruses, such as fever, headache, sore throat and aching limbs.
• the active ingredients used for treating the cough which is likewise associated with common colds are different and are from the group of expectorants or the group of antitussives such as codeine, dihydrocodeine, hydrocodone, clobutinol, pentoxyverine, pipazetate, noscapine, dextromethorphan or plant constituents.
• Cough is normally regarded as a symptom of a disorder but, apart from idiopathic cough, not as a separate disease.
• Cough (tussis) refers to the voluntary or involuntary, induced via the cough reflex on the basis of an urge to cough, explosive expulsion of air intended to free the airways of foreign bodies or mucus which might block or constrict them. Cough is thus normally one of the body's protective and cleansing mechanisms.
• Cough is differentiated into various types. A distinction is made essentially between dry cough (nonproductive) and the productive cough characterized by copious formation of mucus. A further differentiation is made between acute and chronic cough according to the duration.
• Dry cough is distinguished by spasmodic, severe coughing attacks in which no mucus is expelled. It occurs suddenly and is usually only of short duration, but may also persist for several weeks. In cases of hacking cough, the cough itself does not lead to a reduction in the urge to cough.
• Cold cough is a common symptom of influenzal infections, i.e. of infections almost always caused by viruses of the respiratory organs. Shortly after the viruses have become established in the bronchi, a dry hacking cough develops owing to the mucosal irritation and develops into an expectorant productive cough. If the mucous expectoration is yellowish, greenish or brownish in colour, this is a sign of a bacterial infection. When the cold is declining, the symptoms diminish and the cough is converted back into a dry cough and/or disappears.
• a particular example to be mentioned of nonproductive cough caused by bacteria is whooping cough.
• Whooping cough is a severe infectious disease caused by the bacterium Bordetella pertussis.
• Whopping cough can be divided into three stages. It starts about five to fourteen days after the infection with the so-called “catarrhal stage” which lasts one to two weeks. In this stage, the infected person suffers from influenza-like symptoms such as sneezing, running nose, sore throat, slight cough and moderate fever. This is followed by the stage characteristic of this disease (paroxysmal stage) which lasts about four to six weeks. The cough becomes worse and occurs spasmodically in the form of several successive severe attacks of coughing, followed by a sudden inhalation with a loud gasp. During these attacks of coughing, mucus may be brought up and then vomited.
• the attacks of coughing occur frequently at night and may be induced by external causes such as, for example, physical exertion or psychological factors. Between the attacks of coughing, those affected are usually not incommoded by the disease and do not suffer from fever. In the late stage of the disease, the so-called “convalescent stage”, there is a gradual decline in the episodes of coughing. This phase of nonproductive cough usually lasts, without antibiotic treatment, six to ten weeks after the febrile phase of the disease has resolved.
• possible causes of cough are not only disorders of the respiratory organs but may also be disorders of the heart or stomach.
• intake of medicaments or, in rare cases, a psychological disorder may underlie the cough.
• Cough is treated by administration either of medicaments which promote the expectoration of bronchial secretion (expectorants) or medicaments suppressing the urge to cough (antitussives).
• the expectorants are differentiated according to the mechanism of action into secretolytics or mucolytics which achieve liquefaction of the bronchial secretion, and secretomotor agents which induce an increased transport away of the bronchial mucus.
• secretolytics are acetylcysteine, bromhexine and its metabolite ambroxol, ammonium chloride and guaifenesin, but also plant products such as fennel oil and anise oil.
• antitussives are opiate derivatives and thus prescription only medicaments.
• Examples in use are codeine, dihydrocodeine, dextromethorphan and hydrocodone, which has particularly strong activity and is covered by the narcotics legislation. These substances act via the central nervous system and have, besides a depressant effect on the cough centre in the brainstem, also a calming (sedative) effect.
• Substances which can be employed as alternatives are those having no addictive potential and no sedative effect either.
• This group of active ingredients includes clobutinol and the somewhat less effective pentoxyverine.
• the urge to cough can also be alleviated alternatively by taking certain plant products.
• Medicaments which suppress the urge to cough should be given only for nonproductive cough. Combination with mucolytic agents (expectorants) is counterproductive because it is then not possible to cough up the mucus produced.
• EP 0 274 845 A1 discloses a stable, solid pharmaceutical preparation which comprises ibuprofen or a pharmaceutically acceptable salt of ibuprofen in combination with codeine or a pharmaceutically acceptable salt of codeine and an insoluble salt of carboxymethylcellulose in an amount preventing discoloration of the preparation.
• ibuprofen is employed exclusively as analgesic or as antipyretic together with the antitussive.
• ibuprofen or another non-steroidal anti-inflammatory drug as single-drug product for the treatment of cough as symptom of diseases caused by viruses or bacteria in the respiratory organs, especially of coryzal conditions, is not known.
• the present invention relates to the use of a non-steroidal anti-inflammatory drug for the treatment of nonproductive cough caused by viruses or bacteria, and for the manufacture of a medicament for the treatment of nonproductive cough caused by viruses or bacteria, especially in the phase of the disorder when the hacking cough is diminishing.
• the non-steroidal anti-inflammatory drug is preferably an inhibitor of cyclooxygenase, both a selective and a nonselective inhibitor of cyclooxygenase being possible.
• the non-steroidal anti-inflammatory drug is selected from the group consisting of non-selective cyclooxygenase inhibitors.
• non-selective cyclooxygenase inhibitors which are suitable for the use according to the invention and may be selected are ibuprofen, acetylsalicylic acid, methyl salicylate, diflunisal, benorylate, naproxen, diclofenac, sulindac, carprofen, fenoprofen, flurbiprofen, ketoprofen, ketorolac, loxoprofen, indomethacin, tiaprofenic acid, mefenamic acid, meclofenamic acid, phenylbutazone, oxyphenbutazone, meloxicam, lornoxicam, piroxicam and nimesulide.
• the non-steroidal anti-inflammatory drug is selected from the group of selective inhibitors of cyclooxygenase 2.
• selective cyclooxygenase 2 inhibitors which are suitable for the use according to the invention and may be selected are celecoxib, lumiracoxib, etoricoxib, parecoxib, valdecoxib and rofecoxib.
• selective and/or nonselective inhibitors of cyclooxygenase for the purpose of the invention.
• the selective and nonselective cyclooxygenase inhibitors may in preferred embodiments of the present invention also be used in the form of their pharmacologically acceptable salts.
• ibuprofen is used as active pharmaceutical ingredient for the manufacture of the medicament for the treatment of cough caused by viruses or bacteria. It is possible in this connection to use ibuprofen both in the form of a racemic mixture of its two enantiomers (R-ibuprofen and S-ibuprofen) and in the form of one of its two enantiomers, the pharmacologically active S-ibuprofen, or R-ibuprofen which is converted in vivo into the pharmacologically active S-ibuprofen, as well as a salt or hydrate thereof.
• the medicament for the treatment of nonproductive cough caused by viruses or bacteria is a single-drug product, i.e. a medicament which comprises one non-steroidal anti-inflammatory drug, preferably ibuprofen or a pharmaceutically acceptable salt or derivative of ibuprofen, as sole active pharmaceutical ingredient.
• this single-drug product is that the non-steroidal anti-inflammatory drug alleviates, in a common cold caused by viruses, not only the symptom of cough but also the other usual symptoms of fever and pain (headaches, aching limbs and muscles) without intake of further medicaments being necessary.
• Active ingredient Amount of active ingredient present as unit dose in formulations of various non-steroidal anti-inflammatory drugs Active ingredient Amount of active ingredient [mg] Ibuprofen 200, 400, 600, 800 Ketoprofen 50, 100, 200 Naproxen 220, 250, 500, 660, 750 Diclofenac 12.5, 25, 50, 100 Celecoxib 100, 200 Rofecoxib 12.5, 25 Valdecoxib 10, 20, 40
• the medicaments obtainable according to the use according to the invention may comprise the non-steroidal anti-inflammatory drug in usual dosages which depend on the active pharmaceutical ingredient used.
• examples of usual amounts of active ingredient present as unit doses in formulations of non-steroidal anti-inflammatory drugs are listed in Table 1.
• the medicament may comprise a dose of from 50 to 3000 mg, preferably from 100 to 800 mg and particularly preferably from 200 to 400 mg ibuprofen-equivalent amount of active ingredient.
• the non-steroidal anti-inflammatory drug is used in combination with an antitussive to manufacture a medicament for the treatment of nonproductive cough caused by viruses or bacteria.
• the medicament obtainable according to the invention represents a combination of at least one non-steroidal anti-inflammatory drug with at least one antitussive.
• the advantage of a medicament according to this embodiment is that the suppressant effect of the antitussive on the urge to cough can be enhanced by the non-steroidal anti-inflammatory drug.
• “Combination” means in the context of the invention not only dosage forms which comprise all the components (so-called fixed combinations), and combination packs which comprise the components separate from one another, but also components which can be administered simultaneously or successively as long as they are employed for the treatment of the same disease/symptom.
• the synergistic effect of the combination of the invention is preferably observed when the non-steroidal anti-inflammatory drug and the antitussive are present in a ratio of from 2:1 to 100:1, preferably 2.5:1 to 20:1, particularly preferably 5:1 to 10:1.
• “Ratio” means in the context of the invention the ratio by weight of the individual components of the combination.
• the recommended daily dose for antitussives is 30 to 180 mg for codeine, 30 to 90 mg for dextromethorphan, 30 to 90 mg for dihydrocodeine, up to 150 mg for noscapine, up to 200 mg for pentoxyverine and 120 to 240 mg for clobutinol.
• the daily dose of antitussive to be administered can be reduced by the combination of the invention with a non-steroidal anti-inflammatory drug by up to 30%, preferably by up to 50% and particularly preferably by up to 75%.
• the medicaments and pharmaceutical formulations of the invention include dosage forms which can be administered parenterally or orally, with preference for dosage forms for oral administration.
• the medicaments and pharmaceutical formulations of the invention may be solid or liquid dosage forms.
• solid dosage forms are tablets, orally disintegrating tablets, effervescent tablets, sugar-coated tablets, capsules, soft gelatin capsules, powders, granules, pellets, suppositories, and platelets and wafers.
• liquid dosage forms are elixirs, syrups, gels, preferably low-viscosity gels, suspensions and solutions.
• the active ingredients of the medicaments and pharmaceutical formulations of the invention are particularly suitable for formulation in a fixed combination in the form of a solid oral dosage form. It is known that the reliability of intake (compliance) by patients is crucially dependent on the factors of the number of dosage forms per time of intake, and the size and weight of the (solid oral) pharmaceutical. The aim should therefore be to have as small a number as possible of different medicaments to be taken separately (advantage of a fixed combination) and to keep the size and weight of a solid oral dosage form as small as possible without impairing the therapeutic potency. This makes intake as convenient as possible for the patient. Fixed combinations in the form of solid oral pharmaceutical formulations with minimum size and minimum weight achieve maximum patient compliance and a crucial improvement in the safety and reliability of the therapy.
• Release of active ingredients from the medicament can be controlled by modifying the composition of the medicaments or pharmaceutical formulations. For example, it is possible by delayed release of the or of one of the active ingredients in a fixed combination for the onset of action thereof to be time-decoupled even on use of fixed combinations.
• the manufacture of the medicaments and pharmaceutical formulations of the invention for the treatment of nonproductive cough can take place by taking account of the non-steroidal anti-inflammatory drugs to be used according to the invention by use of the processes known for the respective dosage form and with use of pharmaceutical excipients as are familiar to the skilled person.
• the solid dosage forms are manufactured by the generally known standard processes.
• Further ingredients are those which are pharmacologically acceptable and physiologically harmless, for example: as fillers cellulose derivatives (e.g. microcrystalline cellulose), sugar (e.g. lactose), sugar alcohols (e.g. sorbitol, mannitol), inorganic fillers (e.g. calcium phosphates), binders (e.g. polyvinylpyrrolidone, gelatin, starch derivatives and cellulose derivatives), and all further excipients required to manufacture pharmaceutical formulations with the desired properties, e.g. lubricants (magnesium stearate), disintegrants (e.g.
• crosslinked polyvinylpyrrolidone sodium carboxymethylcellulose
• wetting agents e.g. sodium lauryl sulphate
• release-slowing agents e.g. cellulose derivatives, poly(meth)acrylic acid derivatives
• stabilizers e.g. cellulose derivatives, poly(meth)acrylic acid derivatives
• Liquid dosage forms are likewise manufactured by standard methods using pharmaceutically acceptable excipients and comprise the active ingredients either dissolved or suspended. Typical volumes administered of these pharmaceutical preparations are between 1 and 10 ml.
• excipients in these liquid formulations are: solvents (e.g. water, alcohol, natural or synthetic oils such as medium chain triglycerides), solubilizers (e.g. glycerol, glycol derivatives), wetting agents (e.g. polysorbate, sodium lauryl sulphate), and further excipients required to manufacture pharmaceutical formulations with the desired properties, e.g. viscosity-increasing agents, pH correctives, sweeteners and flavourings, antioxidants, stabilizers and/or preservatives.
• solvents e.g. water, alcohol, natural or synthetic oils such as medium chain triglycerides
• solubilizers e.g. glycerol, glycol derivatives
• wetting agents e.g. polysorbate, sodium
• the main ingredient of the shells of capsule formulations are for example gelatin or hydroxypropylmethylcellulose.
• the present invention relates not only to the use of a non-steroidal anti-inflammatory drug for the treatment of nonproductive cough and for the manufacture of a medicament for the treatment of nonproductive cough, but also to pharmaceutical formulations for the treatment of nonproductive cough which comprise the combination of at least one antitussive with at least one non-steroidal anti-inflammatory drug, but also to the use of this combination for the treatment of nonproductive cough as symptom of a disease caused by viruses or bacteria.
• the antitussive and/or the non-steroidal anti-inflammatory drug are preferably selected from the groups of active ingredients mentioned previously.
• the medicaments of the invention may comprise a combination of at least one non-steroidal anti-inflammatory drug with at least one antitussive in a joint dosage form, or be in the form of a “kit” which comprises in separate containers in a single pack in one container an effective amount of at least one non-steroidal anti-inflammatory drug and in another container an effective amount of at least one antitussive.
• the present invention thus also relates to pack units or kits which one or more units of compositions which comprise at least one non-steroidal anti-inflammatory drug, preferably ibuprofen or one of its pharmaceutically acceptable salts, hydrates or derivatives, and/or at least one antitussive and which represent a large number of single doses which are intended to be administered for the treatment of nonproductive cough as symptom of an infection caused by viruses or bacteria.
• the efficacy of ibuprofen in the symptomatic treatment of nonproductive cough was determined in 3 volunteer patients in the final phase of a viral infection.
• the patients received oral administration of 400 or 800 mg of ibuprofen (the daily dose was between 400 and 1200 mg). No other medicaments were taken by the patients during the viral infection.

Landscapes

• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Pulmonology (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Rheumatology (AREA)
• Otolaryngology (AREA)
• Pain & Pain Management (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)

Priority Applications (2)

Applications Claiming Priority (4)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=38819735

Family Applications (3)

Family Applications After (2)

Country Status (9)

Cited By (3)

Citations (3)

Family Cites Families (1)

• 2007
  • 2007-10-09 EP EP07818811A patent/EP2106258B1/de not_active Not-in-force
  • 2007-10-09 PL PL07818811T patent/PL2106258T3/pl unknown
  • 2007-10-09 PT PT07818811T patent/PT2106258E/pt unknown
  • 2007-10-09 ES ES07818811T patent/ES2393128T3/es active Active
  • 2007-10-09 WO PCT/EP2007/008737 patent/WO2008046538A2/de active Application Filing
  • 2007-10-10 AR ARP070104476A patent/AR063228A1/es unknown
  • 2007-10-19 TW TW096139088A patent/TW200831072A/zh unknown
  • 2007-10-19 UY UY30653A patent/UY30653A1/es not_active Application Discontinuation
• 2009
  • 2009-04-20 US US12/386,531 patent/US20100022608A1/en not_active Abandoned
• 2012
  • 2012-06-27 US US13/535,132 patent/US9867789B2/en active Active
• 2017
  • 2017-12-13 US US15/840,872 patent/US20180125792A1/en not_active Abandoned

Patent Citations (3)

Also Published As

Similar Documents

Legal Events